Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Indigenous Bloom Hemp Corp VRTHF

Indigenous Bloom Hemp Corporation is a Canada-based company, which produce and sell hemp extracts. The Company operates a large scale industrial hemp farm in southern Manitoba on approximately 200 acres of zoned farmland. The primary business of the Company is the sale of hemp biomass and flower (Hemp), Phyto cannabinoid rich (PCR) extracts derived from hemp biomass (Hemp Extracts). The Company is in the process of developing, through acquisition and construction, Hemp Products for general consumer end-use. It has two primary products which it plans to sell and is in the process of expanding its product line. The Company’s primary product to date is Hemp Biomass, which is sold pre-processed to customers and partners who process the biomass into Hemp Extracts. The Company has cultivated approximately 100,000 kilograms of Hemp Biomass.


GREY:VRTHF - Post by User

Bullboard Posts
Post by HaulJockeyon Oct 16, 2017 4:10pm
152 Views
Post# 26818489

More Likely This

More Likely ThisOctober 11, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), (“Veritas” or the “Company”) announces the closing of a private placement of units. Under the terms of the Private Placement Offering, the Company will be issuing 3,939,600 Units. Under the terms of the placement, each unit consists of one common share and one share purchase warrant for $0.28 per share. The Company has received $1,027,600. Each share purchase warrant will entitle the holder to acquire an additional share for $0.45 for 18 months following the Closing Date. The Company can reduce the exercise period in the event that the trading price of the Shares is $1.00 or more for a period of ten consecutive days. The Company is paying finders fees totaling 269,600 units. Proceeds from this private placement will used to advance into human trials as outlined on our May 8, 2017 News Release, and for working capital purposes.
Bullboard Posts